1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Strategy

GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

 
• By Malcolm Spicer

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.

GSK Carlisle
GSK is phasing out production at its Carlisle, PA, production facility by mid-2021 and will full exit the site by the end of that year.

Approval in the US of the first OTC prescription-strength, nonsteroidal anti-inflammatory topical gel for arthritis isn’t GlaxoSmithKline PLC’s only recent consumer health development.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Azelis Grows Nutraceuticals Offering In Iberia With Solchem

 
• By Tom Gallen

Azelis adds dietary supplement ingredients and a large customer base across Spain to its portfolio with the acquisition of Solchem Nature.

People On The Move: Appointments At Maxwellia, Nestlé, Alland & Robert

 
• By Tom Gallen

A round-up of the latest European health & wellness market moves: Maxwellia names chief operating officer; Nestle appoints marketing & sales head; Alland & Robert gets deputy general manager.

Givaudan Has UTI Health Claim Turned Down In EU

 
• By Tom Gallen

European Food Safety Authority finds no cause and effect relationship between Givaudan's Pacran supplement and defense against urinary tract infections.

ProBiotix Health Looks To Next Level In Korea’s $450m Probiotics Market

 
• By Tom Gallen

Agreement with Seoul-based health and wellness player TopHealth will see the roll out of ProBiotix' cholesterol-lowering probiotics in South Korea.

More from Business

Good News? 90-Day Pause On Most Tariff Changes – Bad News? 125% Rate Imposed Against China

 
• By Malcolm Spicer

US businesses across industry sectors remain apprehensive about higher tariffs going into effect on imports from China after three-month pause allowed on other changes.

KKR Expands Health & Beauty Portfolio With Deal For Sweden’s Karo

 
• By Tom Gallen

Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.

Clasado Divests Bimuno Prebiotic Consumer Brand To UK’s Eleat

 
• By David Ridley

Eleat's acquisition encompasses Clasado's Bimuno finished supplement product line and customer base, but not its Bimuno GOS proprietary galactooligosaccharide prebiotic ingredient.